Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 5Atripla

02 12Biktarvy

03 1Complera

04 1Complera /Eviplera

05 8Complera/Eviplera

06 14Descovy

07 20Genvoya

08 14Odefsey

09 5Prezista/Prezcobix/Rezolsta/Symtuza

10 7Revenue share - Symtuza

11 15Stribild

12 9Symtuza

13 9Truvada

PharmaCompass

01

Brand Name : Biktarvy

Emtricitabine

arrow
RDD
Not Confirmed

Brand Name : Biktarvy

arrow
RDD
Not Confirmed

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 7,259

2019 Revenue in Millions : 4,738

Growth (%) : 53

blank

02

arrow
RDD
Not Confirmed

03

arrow
RDD
Not Confirmed

04

arrow
RDD
Not Confirmed

05

arrow
RDD
Not Confirmed

06

Brand Name : Complera/Eviplera

Emtricitabine

arrow
RDD
Not Confirmed

Brand Name : Complera/Eviplera

arrow
RDD
Not Confirmed

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 269

2019 Revenue in Millions : 406

Growth (%) : -34

blank

07

Brand Name : Stribild

Emtricitabine

arrow
RDD
Not Confirmed

Brand Name : Stribild

arrow
RDD
Not Confirmed

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 196

2019 Revenue in Millions : 369

Growth (%) : -47

blank

08

arrow
RDD
Not Confirmed

09

Brand Name : Truvada

Emtricitabine

arrow
RDD
Not Confirmed

Brand Name : Truvada

arrow
RDD
Not Confirmed

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 1,448

2019 Revenue in Millions : 2,813

Growth (%) : -49

blank

10

arrow
RDD
Not Confirmed